The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Ultragenyx Pharmaceutical Inc.’s stock clocked out at $44.02, down -0.50% from its previous closing price of $44.24. In other words, the price has decreased by -$0.50 from its previous closing price. On the day, 0.63 million shares were traded. RARE stock price reached its highest trading level at $45.36 during the session, while it also had its lowest trading level at $43.92.
Ratios:
To gain a deeper understanding of RARE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on April 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 18 ’24 when Crombez Eric sold 142 shares for $44.10 per share. The transaction valued at 6,262 led to the insider holds 48,785 shares of the business.
Kassberg Thomas Richard sold 11,509 shares of RARE for $574,644 on Mar 11 ’24. The CBO & EVP now owns 252,823 shares after completing the transaction at $49.93 per share. On Mar 07 ’24, another insider, Fust Matthew K, who serves as the Director of the company, sold 12,195 shares for $50.88 each. As a result, the insider received 620,443 and left with 14,860 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3642531840 and an Enterprise Value of 3981944064. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.35 while its Price-to-Book (P/B) ratio in mrq is 13.16. Its current Enterprise Value per Revenue stands at 9.17 whereas that against EBITDA is -7.331.
Stock Price History:
The Beta on a monthly basis for RARE is 0.67, which has changed by 0.03552103 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is -7.89%, while the 200-Day Moving Average is calculated to be 4.50%.
Shares Statistics:
It appears that RARE traded 696.66K shares on average per day over the past three months and 688530 shares per day over the past ten days. A total of 82.31M shares are outstanding, with a floating share count of 77.02M. Insiders hold about 6.45% of the company’s shares, while institutions hold 104.07% stake in the company. Shares short for RARE as of 1713139200 were 4382486 with a Short Ratio of 6.29, compared to 1710460800 on 3780931. Therefore, it implies a Short% of Shares Outstanding of 4382486 and a Short% of Float of 5.54.
Earnings Estimates
A detailed examination of Ultragenyx Pharmaceutical Inc. (RARE) is currently in progress, with 17.0 analysts providing valuable insights into its market dynamics.On average, analysts expect EPS of -$1.75 for the current quarter, with a high estimate of -$1.39 and a low estimate of -$2.04, while EPS last year was -$2.33. The consensus estimate for the next quarter is -$1.64, with high estimates of -$1.36 and low estimates of -$2.01.
Analysts are recommending an EPS of between -$5.23 and -$8.32 for the fiscal current year, implying an average EPS of -$6.45. EPS for the following year is -$5.04, with 19.0 analysts recommending between -$1.58 and -$7.05.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $116.36M. It ranges from a high estimate of $124.6M to a low estimate of $98.8M. As of the current estimate, Ultragenyx Pharmaceutical Inc.’s year-ago sales were $100.5MFor the next quarter, 16 analysts are estimating revenue of $125.25M. There is a high estimate of $130.1M for the next quarter, whereas the lowest estimate is $120.38M.
A total of 18 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $530.01M, while the lowest revenue estimate was $499.73M, resulting in an average revenue estimate of $513.08M. In the same quarter a year ago, actual revenue was $434.25MBased on 19 analysts’ estimates, the company’s revenue will be $642.09M in the next fiscal year. The high estimate is $920.7M and the low estimate is $541.73M.
